Aoxin Q & M Dental Group (1D4) Fair Value & Analysis
Healthcare · SG · Market cap 278M SGD
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price −16.7% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.0360 SGD – 0.3150 SGD · the 0.2500 SGD price screens above the 0.0300 SGD fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Aoxin Q & M Dental Group (1D4) currently trades at 0.2500 SGD, while our model-based Fair Value estimate is 0.0300 SGD — implying the stock looks roughly 88.0% overvalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Aoxin Q & M Dental Group generated revenue of 176M SGD at a net margin of 4.0%. Revenue declined 8.9% year over year. It earns a return on equity of 2.3%. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Aoxin Q & M Dental Group Limited, an investment holding company, provides private dental healthcare services in the People's Republic of China and Singapore. It operates through three segments: Primary Healthcare; Distribution of Dental Equipment and Supplies; and Laboratory Services. It offers private dental services, such as stomatology and general dentistry, endodontics, orthodontics, periodontics, prosthodontics, dental implantology, oral and maxillofacial surgery, aesthetic dentistry, and paedodontics; and operates dental centers comprising dental polyclinics and dental hospitals in Liaoning Province. The company also distributes and sells dental equipment and supplies, such as dental chairs, ultrasound scanners, dental instruments, and materials and consumables to dental hospitals, clinics, distributors, and laboratories. In addition, it provides laboratory services, which includes the manufacturing of porcelain crown, bridges, and dentures; and leases medical equipment. …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Aoxin Q & M Dental Group reported revenue of 171M SGD in FY2025 versus 160M SGD in FY2021, a compound +1.7%/yr. Reported net income was 7.0M SGD in FY2025.
Is 1D4 fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.27 | $8.25 | -27% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.70 MYR | 2.61 MYR | -70% |
| IHHHF IHHHF | $1.71 | $1.26 | -26% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Aoxin Q & M Dental Group (1D4) undervalued?
What is the fair value of 1D4?
What is the quality score of 1D4?
What is the revenue of Aoxin Q & M Dental Group (1D4)?
What is the net profit margin of 1D4?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.